A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Mulitple Myeloma (CaMMouflage Trial)

Protocol No

CARIBOU-CAMMOUFLAGE-CB-011A-MM

Staff Member

Binod Dhakal

Phase

I

Summary

To find out what effects the CB-011 therapy may have on your cancer. For patients with r/r multiple myeloma

Objective

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RR MM

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL